Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2008

Open Access 01-12-2008 | Research

Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma

Authors: Satyabrata Sinha, Ratnesh K Singh, Neyaz Alam, Anup Roy, Susanta Roychoudhury, Chinmay Kumar Panda

Published in: Molecular Cancer | Issue 1/2008

Login to get access

Abstract

Introduction

Younger women with breast carcinoma (BC) exhibits more aggressive pathologic features compared to older women; young age could be an independent predictor of adverse prognosis. To find any existing differences in the molecular pathogenesis of BC in both younger and older women, alterations at chromosomal (chr.) 9q22.32-22.33 region were studied owing to its association in wide variety of tumors. Present work focuses on comparative analysis of alterations of four candidate genes; PHF2, FANCC, PTCH1 and XPA located within 4.4 Mb region of the afore-said locus in two age groups of BC, as well as the interrelation and prognostic significance of alterations of these genes.

Methods

Deletion analysis of PHF2, FANCC, PTCH1 and XPA were examined in a subset of 47 early-onset (group-A: ≤ 40 years) and 59 late-onset (group-B: > 40 years) breast carcinomas using both microsatellite and exonic markers. Methylation Sensitive Restriction analysis (MSRA) was done to check for promoter methylation. Quantitative real-time polymerase chain reaction (Q-PCR) and immunohistochemisty (IHC) was done in some genes to see their relative mRNA and protein expressions respectively. Clinico-pathological correlation of different parameters as well as patient survival was calculated using different statistical softwares like EpiInfo 6.04b, SPSS 10.0 etc.

Results

Either age group exhibited high frequency of overall alterations in PHF2, FANCC and PTCH1 compared to XPA. Samples with alteration (deletion/methylation) in these genes showed reduced level of mRNA expression as seen by Q-PCR. Immunohistochemical analysis of FANCC and PTCH1 also supported this observation. Poor patient survival was noted in both age groups having alterations in FANCC. Similar result was also seen with PTCH1 and XPA alterations in group-A and PHF2 alterations in group-B. This reflected their roles as prognostic tools in the respective groups in which they were altered.

Conclusion

Overall alterations of PHF2, FANCC and PTCH1 were comparatively higher than XPA. Differential association of alterations in FANCC and PTCH1 with that of PHF2, XPA and two breast cancer susceptibility genes (BRCA1/BRCA2) in the two age groups suggests differences in their molecular pathogenesis and dysregulation of multiple DNA repair pathways as well as hedgehog dependent stem cell renewal pathway.
Appendix
Available only for authorised users
Literature
1.
Sen U, Sankaranarayanan R, Mandal S, Ramanakumar AV, Parkin DM, Siddiqi M: Cancer patterns in eastern India: the first report of the Kolkata cancer registry. Int J Cancer. 2002, 100: 86-91. 10.1002/ijc.10446CrossRefPubMed
2.
Chung M, Chang HR, Bland KI, Wanebo HJ: Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996, 77: 97-103. 10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3CrossRefPubMed
3.
Chunder N, Mandal S, Basu D, Roy A, Roychoudhury S, Panda CK: Deletion mapping of chromosome 1 in early onset and late onset breast tumors–a comparative study in eastern India. Pathol Res Pract. 2003, 199: 313-321. 10.1078/0344-0338-00423CrossRefPubMed
4.
Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK: Analysis of different deleted regions in chromosome 11 and their interrelations in early- and late-onset breast tumors: association with cyclin D1 amplification and survival. Diagn Mol Pathol. 2004, 13: 172-182. 10.1097/01.pas.0000124337.49401.0bCrossRefPubMed
5.
Foo CS, Su D, Chong CK, Chng HC, Tay KH, Low SC, Tan SM: Breast cancer in young Asian women: study on survival. ANZ J Surg. 2005, 75: 566-572. 10.1111/j.1445-2197.2005.03431.xCrossRefPubMed
6.
Sinha S, Chunder N, Mukherjee N, Alam N, Roy A, Roychoudhury S, Kumar Panda C: Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma. Ann Surg Oncol. 2008, 15: 1070-1080. 10.1245/s10434-007-9790-0CrossRefPubMed
7.
Mitelman F, Mertens F, Johansson B: A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet. 1997, 417-474. 15 Spec No.
8.
Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, Gray JW: Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA. 2001, 98: 7952-7957. 10.1073/pnas.151241198PubMedCentralCrossRefPubMed
9.
Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, Clemmer V, Zaks TZ, Weber BL: High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 2005, 7: R1186-1198. 10.1186/bcr1356PubMedCentralCrossRefPubMed
10.
Korsching E, Packeisen J, Helms MW, Kersting C, Voss R, van Diest PJ, Brandt B, Wall van der E, Boecker W, Burger H: Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer. 2004, 90: 1422-1428. 10.1038/sj.bjc.6601658PubMedCentralCrossRefPubMed
11.
Lichun Y, Ching Tang CM, Wai Lau K, Lung ML: Frequent loss of heterozygosity on chromosome 9 in Chinese esophageal squamous cell carcinomas. Cancer Lett. 2004, 203: 71-77. 10.1016/j.canlet.2003.09.027CrossRefPubMed
12.
Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y: Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000, 19: 6317-6323. 10.1038/sj.onc.1204022CrossRefPubMed
13.
Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y: Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene. 1999, 18: 157-163. 10.1038/sj.onc.1202277CrossRefPubMed
14.
Nowakowska B, Kutkowska-Kazmierczak A, Stankiewicz P, Bocian E, Obersztyn E, Ou Z, Cheung SW, Cai WW: A girl with deletion 9q22.1-q22.32 including the PTCH and ROR2 genes identified by genome-wide array-CGH. Am J Med Genet A. 2007, 143A: 1885-1889. 10.1002/ajmg.a.31845CrossRefPubMed
15.
D'Alessandro M, Coats SE, Morley SM, Mackintosh L, Tessari G, Turco A, Gerdes AM, Pichert G, Whittaker S, Brandrup F: Multiple self-healing squamous epithelioma in different ethnic groups: more than a founder mutation disorder?. J Invest Dermatol. 2007, 127: 2336-2344. 10.1038/sj.jid.5700914CrossRefPubMed
16.
Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ: Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2007, 69: 218-225.CrossRefPubMed
17.
Haneline LS, Gobbett TA, Ramani R, Carreau M, Buchwald M, Yoder MC, Clapp DW: Loss of FancC function results in decreased hematopoietic stem cell repopulating ability. Blood. 1999, 94: 1-8.PubMed
18.
Habi O, Delisle MC, Messier N, Carreau M: Lack of self-renewal capacity in Fancc-/- stem cells after ex vivo expansion. Stem Cells. 2005, 23: 1135-1141. 10.1634/stemcells.2004-0356CrossRefPubMed
19.
Kitao H, Yamamoto K, Matsushita N, Ohzeki M, Ishiai M, Takata M: Functional interplay between BRCA2/FancD1 and FancC in DNA repair. J Biol Chem. 2006, 281: 21312-21320. 10.1074/jbc.M603290200CrossRefPubMed
20.
Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, Hader C, Hartmann FH, Nanda I, Steinlein C: Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res. 2007, 118: 166-176. 10.1159/000108297CrossRefPubMed
21.
Heijden van der MS, Yeo CJ, Hruban RH, Kern SE: Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003, 63: 2585-2588.PubMed
22.
Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, Petersen G: Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005, 65: 383-386.PubMed
23.
Shahi MH, Lorente A, Castresana JS: Hedgehog signalling in medulloblastoma, glioblastoma and neuroblastoma. Oncol Rep. 2008, 19: 681-688.PubMed
24.
Reifenberger J, Arnold N, Kiechle M, Reifenberger G, Hauschild A: Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. J Invest Dermatol. 2001, 116: 472-474.CrossRefPubMed
25.
Adolphe C, Hetherington R, Ellis T, Wainwright B: Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006, 66: 2081-2088. 10.1158/0008-5472.CAN-05-2146CrossRefPubMed
26.
Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP: Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat. 2007, 105: 139-155. 10.1007/s10549-006-9440-4CrossRefPubMed
27.
Asahina H, Kuraoka I, Shirakawa M, Morita EH, Miura N, Miyamoto I, Ohtsuka E, Okada Y, Tanaka K: The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. Mutat Res. 1994, 315: 229-237.CrossRefPubMed
28.
Kuraoka I, Morita EH, Saijo M, Matsuda T, Morikawa K, Shirakawa M, Tanaka K: Identification of a damaged-DNA binding domain of the XPA protein. Mutat Res. 1996, 362: 87-95.CrossRefPubMed
29.
Patrick SM, Turchi JJ: Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity. J Biol Chem. 2002, 277: 16096-16101. 10.1074/jbc.M200816200CrossRefPubMed
30.
Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis. 2006, 27: 1670-1675. 10.1093/carcin/bgi376CrossRefPubMed
31.
Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X: Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res. 2007, 13: 3753-3758. 10.1158/1078-0432.CCR-06-1911CrossRefPubMed
32.
Takebayashi Y, Nakayama K, Kanzaki A, Miyashita H, Ogura O, Mori S, Mutoh M, Miyazaki K, Fukumoto M, Pommier Y: Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors. Cancer Lett. 2001, 174: 115-125. 10.1016/S0304-3835(01)00690-5CrossRefPubMed
33.
Hasenpusch-Theil K, Chadwick BP, Theil T, Heath SK, Wilkinson DG, Frischauf AM: PHF2, a novel PHD finger gene located on human chromosome 9q22. Mamm Genome. 1999, 10: 294-298. 10.1007/s003359900989CrossRefPubMed
34.
Sobin LH, Wittekind C: TNM Classification of Malignant Tumors. 2002, New York: Wiley, 6.
35.
Dasgupta S, Mukherjee N, Roy S, Roy A, Sengupta A, Roychowdhury S, Panda CK: Mapping of the candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of an Indian patient population. Oral Oncol. 2002, 38: 6-15. 10.1016/S1368-8375(00)00131-7CrossRefPubMed
36.
Tripathi Bhar A, Banerjee S, Chunder N, Roy A, Sengupta A, Roy B, Roychowdhury S, Panda CK: Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol. 2003, 129: 642-650. 10.1007/s00432-003-0485-zCrossRefPubMed
37.
Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. 2000, 60: 417-424.PubMed
38.
Loginov VI, Maliukova AV, Seregin Iu A, Khodyrev DS, Kazubskaia TP, Ermilova VD, Gar'kavtseva RF, Kiselev LL, Zabarovskii ER, Braga EA: [Methylation of the promoter region of the RASSF1A gene, a candidate tumor suppressor, in primary epithelial tumors]. Mol Biol (Mosk). 2004, 38: 654-667.CrossRef
39.
Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F, Kisseljova N: Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer. 2002, 2: 4- 10.1186/1471-2407-2-4PubMedCentralCrossRefPubMed
40.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRefPubMed
41.
Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat. 2001, 67: 61-70. 10.1023/A:1010623308275CrossRefPubMed
42.
Chunder N, Mandal S, Roy A, Roychoudhury S, Panda CK: Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors. Ann Surg Oncol. 2004, 11: 1045-1055. 10.1245/ASO.2004.02.022CrossRefPubMed
43.
Mizuno T, Tokuoka S, Kishikawa M, Nakashima E, Mabuchi K, Iwamoto KS: Molecular basis of basal cell carcinogenesis in the atomic-bomb survivor population: p53 and PTCH gene alterations. Carcinogenesis. 2006, 27: 2286-2294. 10.1093/carcin/bgl107CrossRefPubMed
Metadata
Title
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: Pathological significance in early- and late-onset breast carcinoma
Authors
Satyabrata Sinha
Ratnesh K Singh
Neyaz Alam
Anup Roy
Susanta Roychoudhury
Chinmay Kumar Panda
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2008
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-7-84

Other articles of this Issue 1/2008

Molecular Cancer 1/2008 Go to the issue

Research

Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway

Research

Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells

Editorial

Another challenge for scientists

Research

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

Review

Tissue Inhibitor of Metalloproteinases-4. The road less traveled

Research

LIM only 4 is overexpressed in late stage pancreas cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits